Adverum Biotechnologies — Avalanche Biotechnologies — Merger or Acquisition (February 2016)
42 slides from Adverum Biotechnologies's merger presentation, Feb 17, 2016
Slide 1: Gaining Momentum in Gene Therapy
Gaining Momentum in Gene Therapy Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained in this document regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Avalanch
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It This document not constitute a solicitation of any vote or approval. In connection with the proposed transaction, Avalanche intends to file with the SEC a proxy statement of Avalanche, as well as other relevant documents concerning the proposed transaction
Slide 4: Proposed Merger with Annapurna Therapeutics
Proposed Merger with Annapurna Therapeutics Feb 1, 2016 Avalanche and Annapurna announce proposed merger: Creating a leading gene therapy company with a diverse pipeline including new assets targeting rare genetic diseases as well as AAVL’s existing ophthalmic programs Merger Terms: Avalanche to acq
Slide 5: Combined Company Highlights
Combined Company Highlights Diversified pipeline including 6 gene therapy product candidates in ophthalmology and rare disease ANN-001: Initiation of first-in-human trial expected in H2 2016 Industry-leading team in gene therapy and translational medicine, including Ronald Crystal M.D. (Weill Cornel
Slide 6: Next-Generation Discovery Platform Fuels R&D Pipeline
Next-Generation Discovery Platform Fuels R&D Pipeline Stage 1: Create Proprietary Library of AAVs Stage 2: In Vitro and In Vivo Screening Stage 3: Selection of Tissue-Specific AAV Vectors Millions of different AAVs produced through mutagenesis In vitro cell-based testing In vivo testing Screen for a
Slide 7: Avalanche Product Pipeline
Avalanche Product Pipeline *Avalanche receives milestones and royalties and has an option to share development costs and profits Product Candidate Indication Stage of Development Near-Term Milestones Worldwide Commercial Rights Research Preclinical Phase 1/2 AVA-101 Wet AMD Preclinical work ongoing
Slide 8: Annapurna Product Pipeline
Product Candidate Indication Stage of Development Near-Term Milestones Worldwide Commercial Rights Research Preclinical Phase 1/2 ANN-001 A1AT Deficiency First–in-human study H2 2016 ANN-002 Hereditary Angioedema First-in-human study 2017 ANN-003 Friedreich’s Ataxia (cardio) Preclinical work ongoing
Slide 9: Annapurna Pipeline in Detail
ANN-001 for α1 Antitrypsin Deficiency (A1AT) II. ANN-002 for Hereditary Angioedema (HAE) III. ANN-003 for Friedreich’s Ataxia (FA) IV. ANN-004 for Severe Allergy Annapurna Pipeline in Detail
Slide 10: Alpha Antitrypsin (A1AT) Deficiency Overview
Alpha 1 Antitrypsin (A1AT) Deficiency Overview Mutations in SERPINA1 gene lead to A1AT deficiency Autosomal recessive disease resulting in very low levels of A1AT A1AT normally protects the lung from the destructive potential of neutrophil elastase If A1AT levels are low, neutrophil elastase slowly
Slide 11: ANN-001: Pre-Clinical Proof of Concept Studies
ANN-001: Pre-Clinical Proof of Concept Studies Intrapleural injection of AAVrh10 1High Levels of Persistent Expression of A1-Antitrypsin Mediated by the Nonhuman Primate Serotype rh.10 Adeno-associated Virus Despite Preexisting Immunity to Common Human Adeno-associated Viruses, Mol Ther Vol. 13, No.
Slide 12: ANN-001 Product Overview for A1AT Deficiency
ANN-001 Product Overview for A1AT Deficiency Validated target and genetically well defined patient population Expected to significantly reduce treatment burden Shown to provide steady levels of A1AT vs peaks and troughs in preclinical studies Rationale for Gene Therapy Approach Long term expression
Slide 13: ANN-001: Trial Design
ANN-001: Trial Design 1Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial, Lancet 2015; 386: 360–68, Chapman et al. First in Human Dose escalation study Will determine route for 3rd dose of 6.1x1012 pe
Slide 14: Commercial Potential for A1AT Deficiency Treatment
Commercial Potential for A1AT Deficiency Treatment FDA approved augmentation therapy based on biochemical levels of protein in blood and lung Multiple approved therapies on market yet we believe significant commercial opportunity still exists Weekly IV administration necessary = major barrier to ado
Slide 15: Annapurna Pipeline in Detail
I. ANN-001 for α1 Antitrypsin Deficiency (A1AT) ANN-002 for Hereditary Angioedema (HAE) III. ANN-003 for Friedreich’s Ataxia (FA) IV. ANN-004 for Severe Allergy Annapurna Pipeline in Detail
Slide 16: Hereditary Angioedema (HAE) Overview
Hereditary Angioedema (HAE) Overview Life threatening genetic disease with limited therapeutic options Genetic disease resulting in low levels of C1-esterase inhibitor (C1-INH) C1-INH deficiency results in excessive levels of bradykinin Bradykinin causes blood vessels to leak fluid Patients experien
Slide 17: Hereditary Angioedema Still an Unmet Need
Hereditary Angioedema Still an Unmet Need Treatments exist but leave room for improvement Cinryze™ is approved prophylactic treatment for prevention of attacks Requires 2-3 IV infusions per week Shown to reduce attack rate by only 50% Limited to patients with frequent attacks who can tolerate freque
Slide 18: ANN-002 Product Overview for HAE
ANN-002 Product Overview for HAE Validated target: genetic disease caused by lack of C1-esterase inhibitor (C1-INH) Continuous exposure to C1-INH expected to reduce risk of breakthrough attack Rationale for Gene Therapy Approach Preliminary studies in relevant animal models suggest an AAV gene trans
Slide 19: Annapurna Pipeline in Detail
I. ANN-001 for α1 Antitrypsin Deficiency (A1AT) ANN-003 for Friedreich’s Ataxia (FA) IV. ANN-004 for Severe Allergy II. ANN-002 for Hereditary Angioedema (HAE) Annapurna Pipeline in Detail
Slide 20: Friedreich's Ataxia (FA) Overview
Friedreich’s Ataxia (FA) Overview Clear unmet need with well-characterized genetic origin Autosomal recessive disease due to mutation in frataxin (FXN) gene, resulting in low levels of frataxin protein Slowly progressive neurodegenerative disease associated with ultimately deadly hypertrophic cardio
Slide 21: ANN-003: Proof of Concept in Cardiac Mouse Model
ANN-003: Proof of Concept in Cardiac Mouse Model (MCK mouse) IV Administration at 7 weeks showed correction in advanced heart failure Mice given single IV administration of AAV at wk 7, when cardiomyopathy is advanced Active and control arms start out at same baseline at wk 7 Significant and rapid i
Slide 22: ANN-003: Moving from Mouse Proof of Concept to Patient Care
ANN-003: Moving from Mouse Proof of Concept to Patient Care Large animal studies underway to validate delivery strategy Mouse model established minimum vector copies/cell needed for therapeutic threshold Studies in pigs showed that epimyocardial delivery was well tolerated and exceeded therapeutic t
Slide 23: ANN-003 Product Overview for Friedreich's Ataxia
ANN-003 Product Overview for Friedreich's Ataxia Validated target: genetic disease caused by reduced levels of frataxin AAV vector delivers FXN gene to cardiomyocytes to restore mitochondrial function Rationale for Gene Therapy Approach Pre-clinical POC established in robust cardiac mouse model Prev
Slide 24: Annapurna Pipeline in Detail
I. ANN-001 for α1 Antitrypsin Deficiency (A1AT) III. ANN-003 for Friedreich’s Ataxia (FA) ANN-004 for Severe Allergy II. ANN-002 for Hereditary Angioedema (HAE) Annapurna Pipeline in Detail
Slide 25: Severe Allergy Overview
Severe Allergy Overview Large unmet clinical need with no well established therapies Severe allergies cause discomfort and can be fatal Most common cause of anaphylaxis in children presenting to the ER Majority of fatalities due to accidental exposure in patients with known allergies No established
Slide 26: ANN-004 Product Overview for Severe Allergy
ANN-004 Product Overview for Severe Allergy Anti-IgE treatment has been used off label to treat severe allergies Rationale for Gene Therapy Approach Pre-clinical POC established in peanut allergic mouse model Proof-of-Concept Most common cause of anaphylaxis in children Many severe, life threatening
Slide 27: Wet AMD
Wet AMD
Slide 28: Wet AMD Gene Therapy: Next Steps
Wet AMD Gene Therapy: Next Steps Comprehensive pre-clinical wAMD research ongoing Seeking optimal vector, with optimal molecule utilizing best route of delivery Evaluating best path forward considering: Protein expression Consistent delivery Optimal method of administration Next generation vector te
Slide 29: £ © .s o fe) = a ®o 7) o ® xe} o is
£ © .s o fe) = a ®o 7) o ® 2 xe} o is fe) (Ss) 1, AVALANCHE agtttte ities
Slide 30: Avalanche's Next-Generation Vectors Efficiently Penetrate Retina Following ITV Injection
Avalanche’s Next-Generation Vectors Efficiently Penetrate Retina Following ITV injection Novel AAV Variant Variant exhibits modified tropism and potential for improved penetration of retinal layers Novel Proprietary Vector (ITV) AAV Serotype 2 (ITV) Intravitreal
Slide 31: Efficient Cone Delivery Allows Us to Address Diseases with Unmet Need
Efficient Cone Delivery Allows Us to Address a Number of Diseases for Which There is an Unmet Need Stargardt’s Disease Age-related macular degeneration Diabetic retinopathy Color vision deficiencies Cone-rod dystrophy / rod-cone dystrophy Stargardt’s Disease Adult vitelliform macular dystrophy X-lin
Slide 32: AVA-322L and AVA-323M Product Overview for Color Vision Deficiency
AVA-322L and AVA-323M Product Overview for Color Vision Deficiency 1Sharpe LT, Stockman A, Jagle H, Nathans J. Opsin genes, photopigments, color vision and color blindness. In: Gegenfurtner KR, Sharpe LT (eds.) Color Vision. Cambridge UP: Cambridge, 1999. Intravitreal injection to confer better colo
Slide 33: Regeneron Collaboration
Regeneron Collaboration
Slide 34: Regeneron Collaboration (May 2014)
Regeneron Collaboration (May 2014) Collaboration Highlights: Covers up to eight distinct therapeutic targets AVA-311 for X-Linked Retinoschisis is first collaboration program Avalanche option to share up to 35% on profits/ development costs for 2 targets Ocular BioFactoryTM Platform & Gene Therapy E
Slide 35: AVA-311 Product Overview for XLRS
AVA-311 Product Overview for XLRS Potential long-term treatment of juvenile X-linked retinoschisis (XLRS) Optimized AAV vector delivers RS1 gene to maintain integrity of retina Rationale for Gene Therapy Approach High levels of RS1 protein expression in mouse model of XLRS Restoration of normal reti
Slide 36: Company Background
Company Background
Slide 37: Core Capabilities of Combined Company
Core Capabilities of Combined Company 200L in-house production capability expected to be established in Q2 2016 Formulation development for higher vector concentration Creating and optimizing proprietary vectors to target specific tissue types Baculovirus expression system – highly efficient, flexib
Slide 38: Experienced Management Team with Expertise in Ophthalmology, Gene Therapy and Drug Development
Experienced Management Team with Expertise in Ophthalmology, Gene Therapy and Drug Development Avalanche Management Team Paul Cleveland President and Chief Executive Officer Samuel B. Barone, M.D. Chief Medical Officer Shirley Braun, Ph.D VP, Human Resources Mehdi Gasmi, Ph.D Interim CSO and SVP Pha
Slide 39: Avalanche Financial Information
Avalanche Financial Information Cash 12/31/15 Basic Shares Outstanding ProForma Shares Outstanding upon completion of proposed merger with Annapurna Financial Information Existing cash and cash equivalents expected to fund combined company for 36 months $258M* 25.7M 43.3M
Slide 40: Post Merger Key Milestones
Post Merger Key Milestones Mid 2016 update on wet AMD program H2 2016 initiate enrollment of first-in-human trial of ANN-001 for A1AT deficiency H2 2016 provide guidance on ANN-003 timeline for Friedreich’s Ataxia 2016/2017 2017 patient enrollment for first-in-human study of ANN-002 for Hereditary A
Slide 41: Combined Company Highlights
Combined Company Highlights Diversified pipeline including 6 gene therapy product candidates in ophthalmology and rare disease ANN-001 – Initiation of first-in-human trial expected in H2 2016 Industry-leading team in gene therapy and translational medicine, including Dr. Ron Crystal M.D (Weill Corne
Slide 42: Slide 42
Avalanche Biotechnologies — Merger or Acquisition (February 2016) on 6ix